|
Revenue from operations rose 1.51% year on year to Rs369.35 crore in the quarter ended 31 March 2023.
Profit before tax increased 3.06% to Rs 166.21 crore in Q4 FY23 as compared with Rs 161.28 crore in Q4 FY22.
EBITDA declined 36.51% to Rs 185.4 crore in the fourth quarter as compared with Rs 292 crore posted in corresponding quarter last year. EBITDA margin stood at 49% in Q4 FY23 as against 59% in Q4 FY22.
Total expenses declined 2.23% to Rs 214.54 crore in Q4 FY23 as against 219.43 crore in Q4 FY22. Cost of material stood at Rs 95.55 crore (down 26.65% YoY), employee benefir expense was at Rs 25.60 crore (down 17.74% YoY) while finance cost was at Rs 2.30 crore (up 5.5% YoY).
On full year basis, the company's net profit declined 9.37% to Rs 411.29 crore on 1.52% jump in revenue from operations to Rs 1,340.32 crore in FY23 over FY22.
Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of global pharma industry.
The scrip was up 0.26% to Rs 473 on the BSE.
|